<DOC>
	<DOCNO>NCT00400517</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , GM-CSF , may stimulate immune system different way stop tumor cell grow . Thalidomide may stop growth prostate cancer block blood flow tumor . Giving GM-CSF thalidomide surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give GM-CSF together thalidomide work treat patient undergo surgery high-risk prostate cancer .</brief_summary>
	<brief_title>GM-CSF Thalidomide Treating Patients Undergoing Surgery High-Risk Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate impact neoadjuvant sargramostim ( GM-CSF ) thalidomide pathologic response ( histologic P0 , margin positivity , capsular penetration ) , prostate-specific antigen ( PSA ) response , investigational endpoint patient high-risk prostate cancer undergo prostatectomy . - Determine safety feasibility GM-CSF thalidomide . OUTLINE : This open-label study . Patients receive sargramostim ( GM-CSF ) subcutaneously day 1 , 3 , 5 oral thalidomide day 1-5 1-7 week 1-4 . Treatment repeat every 4 week 2 course absence unacceptable toxicity . Patients undergo radical prostatectomy bilateral pelvic lymphadenectomy week 8 9 . PROJECTED ACCRUAL : A total 29 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate meeting follow criterion highrisk disease : Clinical stage II III ( T2b , T2c , T3 grade prostatespecific antigen [ PSA ] ) Gleason score 7 ( 4+3 ) ≥ 8 ( stage PSA ) Serum PSA ≥ 10 ng/dL ( grade stage ) Any stage , PSA , Gleason score ≥ 35 % chance biochemical failure 5 year base Kattan 's nomogram No clinical evidence CNS metastases No metastatic disease demonstrate radiological exam ( CT scan , MRI , bone scan , xray ) within 8 week study entry Appropriate medical candidate radical prostatectomy PATIENT CHARACTERISTICS : ECOG performance status 01 Creatinine ≤ 2.0 mg/dL Granulocyte count ≥ 1,800/mm³ Platelet count ≥ 100,000/mm³ AST &lt; 3 time upper limit normal Bilirubin ≤ 1.5 mg/dL Fertile patient must use effective contraception 4 week completion study treatment No active unresolved infection No preexist peripheral neuropathy &gt; grade 1 No know HIV positivity No malignancy within past 5 year except curatively treat basal cell squamous cell carcinoma skin control Ta transitional cell carcinoma bladder No know contraindication sargramostim ( GMCSF ) thalidomide PRIOR CONCURRENT THERAPY : No prior radiotherapy prostate pelvis No prior chemotherapy hormonal therapy prostate cancer No parenteral antibiotic within past 7 day</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>